In this issue:
First-line immuno-oncology combination therapies in mRCC
Renin is a prognostic factor for recurrence in nonmetastatic ccRCC
VHL synthetic lethality signatures identified by CRISPR screens
HAR immunotherapy in patients with refractory mRCC
Atezolizumab + bevacizumab vs sunitinib in previously untreated mRCC
Nivolumab + ipilimumab vs sunitinib in first-line treatment for advanced RCC
Guideline adherence for the surgical treatment of T1 renal tumours correlates with hospital volume
Safety of CN following sunitinib
Extended duration of active surveillance of small renal masses
Use of targeted therapies for advanced RCC in a real-world setting
Please login below to download this issue (PDF)